The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

Like tens of thousands of Massachusetts residents, community college professor Carolyn McGrath has been paying for medicine ...

Amid inflation, tariffs, shifting consumer behaviors and supply chain upheavals, landlords and retailers are turning ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

So far this year, Pfizer shares have dropped 17.4%, while Novo Nordisk's stock has tumbled 24% and Lilly shares have slipped 3.2%. The SPDR S&P Pharmaceuticals ETF XPH has shed 12.1% year to date and ...

States increasingly struggling to cover the rising cost of popular GLP-1 drugs like Wegovy, Ozempic and Zepbound are ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...

As demand soared for weight-loss drugs, price signals worked.